A platform business in agricultural biotechnology
Exacta BioScience operates a biodiscovery-to-scale-up platform researching bacteriophage and beneficial-bacteria technologies — built in Chile, with a path to global reach.
Conventional tools are running out of road
Bacterial diseases cost growers yield and quality every season. The chemical tools that have controlled them for decades — copper, antibiotics — are under pressure from three directions at once: documented bacterial resistance, tightening maximum residue limits (MRLs) in premium export markets, and regulatory restriction of key antibiotics. That combination is opening structural demand for biological alternatives with a genuinely different mode of action.
- Resistance to copper and streptomycin is documented and growing in several agriculturally important bacterial pathogens
- Export markets are tightening MRLs, raising the cost of residue-based rejections
- Biological crop protection is one of the fastest-growing segments of the broader crop-protection market
- High-value, export-oriented crops are the segment most exposed to this problem
One engine, a research pipeline
Exacta's biodiscovery, formulation and scale-up infrastructure is reusable across pathogens, crops and technologies — it is not built around a single molecule or a single disease.
Two research lines
Bacteriophages (host-specific, self-limiting, residue-free) and beneficial bacteria (plant growth support and microbial ecology).
A diversified research pipeline
Multiple research programmes spanning several bacterial disease targets, crop systems and development stages.
Built for scale
Formulations designed for stability at room temperature, with production processes built for cost-effective supply, not just lab-scale proof of concept.
Validated by grants, capital and commercial partners
$1M USD financing round
Raised to accelerate platform development and scale-up capacity.
CORFO & ANID grant-backed R&D
Chile's national innovation and science agencies have co-funded platform development.
A biological portfolio already commercially available
Exacta technology already reaches Chilean growers through a specialised distribution partner.
International expansion underway
A strategic alliance is extending Exacta's distribution reach into Brazil, one of the world's largest agricultural markets.
Backed by specialist investors
A dedicated venture capital investor is among those supporting Exacta's platform.
Backed by partners and institutions
-
Public research funding -
Public research funding -
Partner -
Distributor (Chile) -
Investor
Global potential, export-market discipline
Exacta's research targets track major global export crops, not a single domestic market. Active development across multiple geographies, an international distribution alliance, and a platform built to premium-export residue standards give it a natural path beyond its home market.
What we're looking for
We are in conversation with investors and strategic partners — agtech investors, CVCs, crop-protection companies, and licensing or R&D partners — who can help accelerate platform development, scale production capacity, and expand into new geographies. If that's you, we'd like to talk.